Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies
about
Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick GetawayReverse vaccinology 2.0: Human immunology instructs vaccine antigen designAntigenic Characterization of the HCMV gH/gL/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human AntibodiesA derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cellsHuman Cytomegalovirus gH/gL/gO Promotes the Fusion Step of Entry into All Cell Types, whereas gH/gL/UL128-131 Broadens Virus Tropism through a Distinct Mechanism.Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody.Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.Vaccine candidate discovery for the next generation of malaria vaccines.Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection agaThe Human Cytomegalovirus UL116 Gene Encodes an Envelope Glycoprotein Forming a Complex with gH Independently from gLPlatelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer.Monoclonal Antibodies to Different Components of the Human Cytomegalovirus (HCMV) Pentamer gH/gL/pUL128L and Trimer gH/gL/gO as well as Antibodies Elicited during Primary HCMV Infection Prevent Epithelial Cell Syncytium Formation.Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope proteinNeutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in Pichia pastoris.Human cytomegalovirus: taking the strain.Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.The role of structural proteomics in vaccine development: recent advances and future prospects.Cytomegalovirus Vaccines: Current Status and Future Prospects.Genetic Stability of Bacterial Artificial Chromosome-Derived Human Cytomegalovirus during Culture In Vitro.Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.The proteome of human cytomegalovirus virions and dense bodies is conserved across different strains.Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system.Chemokines encoded by herpesviruses.Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice.Anti-Infectious Human Vaccination in Historical Perspective.The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus.What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise.Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus.Analytic Vaccinology: Antibody-Driven Design of a Human Cytomegalovirus Subunit Vaccine.Exploiting 2A Peptides to Elicit Potent Neutralizing Antibodies by a Multi-Subunit Herpesvirus Glycoprotein Complex.Phenotype and specificity of T cells in primary human cytomegalovirus infection during pregnancy: IL-7Rpos long-term memory phenotype is associated with protection from vertical transmission.Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection.Neutralization of Human Cytomegalovirus Entry into Fibroblasts and Epithelial Cells.Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections.Immune responses to congenital cytomegalovirus infection.Dissecting human antibody responses: useful, basic and surprising findings.Fine-mapping the interaction between DC-SIGN and the cytomegalovirus envelope glycoprotein B.Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
P2860
Q26745798-FEE4DD17-C044-4CC3-B4B4-7270334F73DEQ28075274-4B11B67D-1127-4AB5-A532-7F25D653F56FQ28550400-19512EEF-9BD7-42CF-86C8-1DD7ADDEBCD7Q33558900-FCD0B64A-82EA-47C6-B7F5-E65ACA2301EBQ35913890-CC11094F-3026-46FE-AA90-20E75955D74CQ36084954-EE7D9F57-4A32-48D7-93CF-67155010DF2FQ36281094-9BB8A926-F228-4231-8292-AC940CC0D36BQ36413834-99EB1CB1-0531-4351-A854-2DF19A764F2AQ36633558-647BA768-55C8-4D60-9F54-4AE048004B4FQ36878894-22DA86DC-35D5-4857-8AC6-AB41EF9A9A76Q37032510-952E7E25-CF24-45BD-9029-223EC52B4F88Q37073289-B12D76F9-0FCF-42A7-A8CC-E40975C8FC7BQ37519151-50DFBF39-9058-4CD4-8932-88F53DA3B37CQ37707461-82DCF789-6817-4152-88F3-3EF27B6DE531Q37721762-DAD9575B-A98F-406F-B5FF-AABBB7179630Q38430703-C865F34A-3659-459B-AB67-7E04A27B4C71Q38602178-43590A59-EA61-4FB1-AF25-33B9A3B8FCE1Q38682335-55C3C9C5-9F28-4C4B-9327-58AA23165BD0Q38791353-6C9C6B72-AE2A-4A2B-92CB-F32FEC0C6D93Q38796870-B710958B-B2B5-48FD-B50D-B046BA55B6AFQ38835171-456C418B-82EB-45C6-B9EF-48FF5E50267EQ38904564-07FABFDD-2C85-4D50-92D9-B53F04FE5EEEQ38997531-BDDE20AF-C31C-4083-B235-35DFA2100D17Q40067378-54E4A5F8-13F9-42CB-8E26-BDEED2CB31BCQ40091454-60147378-1473-486C-A858-073F1C031670Q40129444-B901205A-96F7-4578-AE0E-31364E8DE50AQ40190061-161EB116-5EC6-4FC9-82D4-C3EF1F0AEAA0Q40346058-FB76A8D0-8B22-4E26-B076-0F66823B142AQ40375876-80EE21CB-5CB0-4506-946A-3995E1B41DFBQ40715812-7C05BB42-8FED-4D81-9A77-C24D4BCB4BC2Q41921854-BA8C8EA2-464E-4F6F-B830-0FF9A163C85EQ45851061-5DE257C7-81A7-4AAB-94DF-8C2B305A38D7Q47115255-8446B29C-E096-406D-AA51-8D4FD59238D6Q47135919-1E29D099-33FF-47DF-814B-204A8CD174B2Q47167247-F0FAC907-20CC-4121-87C9-2EDA8CEB5786Q47546281-8642556A-71D2-4BC6-A2E5-07BAFD850330Q47559622-4344E8CC-290C-4449-BFC4-3872900895FCQ48023106-7D231CFA-F208-4222-BCC3-9BA85D9DE770Q52323814-2520CADC-138D-4E4D-BF93-ACE0CE428E48Q52568669-5D95DFBA-A58A-497C-9456-87107528A952
P2860
Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Antibody-driven design of a hu ...... potent neutralizing antibodies
@ast
Antibody-driven design of a hu ...... potent neutralizing antibodies
@en
Antibody-driven design of a hu ...... potent neutralizing antibodies
@nl
type
label
Antibody-driven design of a hu ...... potent neutralizing antibodies
@ast
Antibody-driven design of a hu ...... potent neutralizing antibodies
@en
Antibody-driven design of a hu ...... potent neutralizing antibodies
@nl
prefLabel
Antibody-driven design of a hu ...... potent neutralizing antibodies
@ast
Antibody-driven design of a hu ...... potent neutralizing antibodies
@en
Antibody-driven design of a hu ...... potent neutralizing antibodies
@nl
P2093
P2860
P50
P356
P1476
Antibody-driven design of a hu ...... potent neutralizing antibodies
@en
P2093
Antonio Lanzavecchia
Dario Fuschillo
Davide Corti
Federica Sallusto
Giuseppe Gerna
Gloria Agatic
Jessica Marcandalli
Silvia Preite
P2860
P304
17965-17970
P356
10.1073/PNAS.1415310111
P407
P577
2014-12-01T00:00:00Z